e-Therapeutics plc

Destiny Pharma plc is set to become the latest UK biotech to bid farewell to the London Stock Exchange’s Alternative Investment Market (AIM) and will take the private route to access cash for its lat

The UK's e-Therapeutics plc has become the latest biotech to quit the London Stock Exchange’s Alternative Investment Market (AIM), with CEO Ali Mortazavi slamming the lack of risk the country's inve

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. GSK Teams With Ideaya On Synthetic Leth

Below is Scrip ’s monthly roundup, including information from Strategic Transactions , of recent technology transfer agreements between companies and academic or other research institutions. Unite